A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Key facts

Study ID

NCT07654972

Run by

Eli Lilly and Company

People needed

108

Starts

2026-06-24

Expected to finish

2029-04-01

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
• Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
• Have had a self-reported stable weight for 3 months prior to screening

You may not qualify if…

• Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
• Is an individual of childbearing potential (IOCBP)

Where it is running

• ICON Early Phase Services, LLC — San Antonio, Texas, United States (enrolling)
• ICON Early Phase Services, LLC — Salt Lake City, Utah, United States
• Lilly Centre for Clinical Pharmacology — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.